Fmoc-L-Glu(PP)-OH

Fmoc-L-Glu(PP)-OH is an Fmoc-protected L-glutamic acid derivative bearing a side-chain carboxylic acid that is masked as a 2,2,3,3,4,4-hexamethyl-? (PP) type ester protecting group, yielding a stable amino acid building block for peptide assembly. The molecule contains an Fmoc carbamate on the α-amino group, a free α-carboxylic acid for coupling, and a protected γ-carboxyl functionality that can be selectively revealed under peptide-deprotection conditions. The stereogenic center at the α-position is fixed as L, aligning the side-chain geometry with standard glutamate residue incorporation in peptide chemistry. The combination of orthogonal protection and a rigid, polar glutamate framework supports controlled reactivity during solid-phase synthesis and downstream functionalization of the glutamate side chain.

1. Protected Amino Acids

Fmoc-L-Glu(PP)-OH is used within protected amino acid synthesis workflows where orthogonal handling of the α-amino group and the γ-carboxyl side chain is required for reliable peptide coupling. The Fmoc carbamate protects the α-amine during assembly while the PP-protected side-chain carboxyl group remains masked to prevent side reactions such as intramolecular cyclization or undesired branching. Selective removal strategies compatible with peptide deprotection can expose the glutamate side-chain carboxyl for subsequent derivatization or for generating authentic glutamate residues in final products. The resulting protected glutamic acid intermediate supports reproducible construction of polar peptide segments and facilitates controlled functional-group exposure for later stages of synthesis.

2. Peptide Synthesis

Fmoc-L-Glu(PP)-OH is applied as a glutamate residue building block for Fmoc-based solid-phase peptide synthesis, where the α-carboxyl and protected α-amine enable standard peptide coupling chemistry. The molecule's L-configuration and glutamate backbone geometry support incorporation into peptide chains with defined stereochemistry at the residue level. The PP-protected γ-carboxyl suppresses side-chain reactivity during chain elongation, helping maintain sequence fidelity and minimizing side reactions that can occur with free acidic side chains under coupling conditions. After assembly, deprotection can restore the γ-carboxyl functionality, enabling synthesis of glutamate-containing peptides, peptide fragments, and protected intermediates suitable for further chemical modification.

3. Side-Chain Functionalization

Fmoc-L-Glu(PP)-OH serves as a precursor for side-chain functionalization strategies targeting the glutamate γ-carboxyl group after orthogonal deprotection. The protected carboxyl allows downstream conversion into activated derivatives such as amides, esters, or other acyl-linked motifs while maintaining the peptide-compatible backbone during earlier steps. The polar, anionic glutamate side chain can be leveraged for conjugation handles in chemical biology and materials-oriented scaffolds once the PP group is removed under controlled conditions. The ability to stage side-chain unveiling from a protected amino acid intermediate supports the preparation of functionalized peptide analogs and chemically defined glutamate-containing conjugates.

4. Chemical Biology Labeling

Fmoc-L-Glu(PP)-OH is suitable for chemical biology research requiring glutamate-functional peptide probes and chemically defined labeling reagents. The Fmoc-protected α-amino group enables incorporation into peptide sequences that can later be deprotected and used as substrates for conjugation chemistries, while the PP-protected γ-carboxyl offers a protected handle during probe construction. Revealed glutamate carboxyl groups can participate in amide-forming coupling to introduce fluorophores, affinity tags, or linkers that support molecular recognition studies. The stereochemically defined glutamate residue and staged functional-group access align with peptide-based probe synthesis and downstream analytical or bioconjugation workflows.

5. Pharmaceutical Manufacturing Intermediates

Fmoc-L-Glu(PP)-OH is relevant to pharmaceutical manufacturing supply chains as a process-compatible protected amino acid intermediate for generating glutamate-containing peptide intermediates at scale. The Fmoc protection strategy supports robust handling during automated peptide assembly, while the PP-protected side-chain carboxyl helps control impurity formation associated with free acidic functionality during manufacturing steps. Deprotection-compatible design supports downstream conversion to deprotected glutamate residues for final API intermediate formation or for producing peptide-related process intermediates. The compound's amino acid framework and protecting-group pattern make it suitable for industrial fine chemical synthesis where reproducible peptide building block quality and predictable deprotection behavior are required.

6. Analytical Research Standards

Fmoc-L-Glu(PP)-OH can be employed in analytical research for preparing reference peptides and side-chain-modified glutamate standards used in method development and characterization. The protected glutamic acid structure enables controlled synthesis of defined peptide sequences, while the staged exposure of the γ-carboxyl group supports generation of standards with specific functional states. Fmoc-based assembly compatibility supports reproducible incorporation into calibration materials for chromatographic and mass spectrometric workflows that distinguish protected versus deprotected carboxyl forms. The stereodefined L-glutamate residue and protection-controlled derivatization support accurate analytical comparisons across peptide synthesis and deprotection stages.

1. Urinary Metabolites Associated with Blood Pressure on a Low-or High-Sodium Die

2. SERS spectrum of the peptide thymosin‐β4 obtained with Ag nanorod substrate

3. Oleic acid and glucose regulate glucagon-like peptide 1 receptor expression in a rat pancreatic ductal cell line

4. Effect of Probiotic Lactobacillus plantarum on Streptococcus mutans and Candida albicans Clinical Isolates from Children with Early Childhood Caries

5. Novel Peptide-Based PD1 Immunomodulators Demonstrate Efficacy in Infectious Disease Vaccines and Therapeutics